Innovative solution for interpreting experimental genomics, transcriptomics and proteomics data with available scientific knowledge so organisations can make faster, well-informed research decisions
Affibody and InforSense have announced the release of KDE GeneSense - an innovative solution for interpreting experimental genomics, transcriptomics and proteomics data with available scientific knowledge so organisations can make faster, well-informed research decisions.
By speeding the interpretation of discovery results, often a rate-limiting step, GeneSense will support and accelerate the identification and validation of potential drug targets.
GeneSense couples InforSense's advanced Kensington Discovery Edition (KDE) discovery informatics environment with Affibody's unique data management, biological annotation (ontology) and visual representation technology.
The result is a novel way to explore functional genomics data using a wealth of annotation data sources for effectively interpreting and verifying discoveries.
For example, in gene expression studies, the fact that certain genes are regulated in an experiment is detected in the primary analysis of microarray data.
How they are regulated in particular patterns can be shown by secondary numerical analysis and pattern finding. However, to understand why they exhibit the observed patterns, a new dimension of analysis is needed, where the experimental results are projected on a semantic network of background knowledge, including pre-defined bioinformatics annotation databases and the user's own ontologies.
GeneSense effectively addresses this interpretation bottleneck by providing researchers with integrated and curated access to relevant information databases; links to KDE's flexible workflow system with a rich set of powerful analytical tools; interpretation using different knowledge domains/vocabularies defined as ontologies - previously a time-consuming manual task; innovative and easy-to use 'virtual chip' and 'tree map' visualisers to facilitate the manipulation and display of ontologies; and an ontology authoring tool to enable the construction of researchers' own ontologies. "We are delighted to see this product enter the market on the KDE platform" said Torben Jorgensen, CEO of Affibody. "GeneSense holds enormous potential since it revolutionises the way researchers carry out and interpret biological annotation studies and thus facilitates a faster drug discovery process." "GeneSense fits naturally within InforSense1s strategy to develop, together with leading scientific companies, innovative domain-specific tools that exploit KDE's world class integration of data, data processing and analysis applications," said Yike Guo, CEO of InforSense.
"With GeneSense, discovery results in silico and studies of biological data in KDE can now be interpreted efficiently and effectively.
